Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) and raised its price target to $17 from $14. The price target hike comes on the heels of the stock’s impressive 258% return over the past year.
This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy
M. A. Arkhipov/Shutterstock.com
Canaccord remains confident about the company’s long-term prospects in the aftermath of the company confirming dosing completion in both the REVEAL and ASPIRE trials in the second quarter. The company is currently advancing TSHA-102, an AAV9-based gene therapy for Rett syndrome. The FDA has already cleared initiation of the ASPIRE trial, in which three patients between 2 and 4 years old are to receive a scaled-down 1E15 dose.
Taysha Gene Therapies plans to provide updated Part A data for the trials in the second quarter, once all 12 patients have received at least 12 months of follow-up. On the other hand, interim six-month pivotal data should be available before year-end.
According to Canaccord, the significant milestone gains and clean safety profile in the pivotal trials underscore why Taysha Gene Therapies is a buy.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe, rare genetic disorders of the central nervous system. Their primary focus is TSHA-102, a promising one-time gene therapy for Rett syndrome.
While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 7 Penny Stocks That Aren’t Scams: Best Cheap Stocks to Buy and 8 Best Small-Cap Value Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.